Abdoulaye DERA

Mr. Abdoulaye DERA

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
ADAbdoulaye DERA
Abdoulaye DERA
Armel M. SanouArmel M. Sanou
Armel M. Sanou
MOMathuola N. G. Ouattara
Mathuola N. G. Ouattara
AIAbdoul K. Ilboudo
Abdoul K. Ilboudo
DLDavid B. Lankoande
David B. Lankoande
MGMichel Kiréopori Gomgnimbou
Michel Kiréopori Gomgnimbou
Hepatitis B e antigen (HBeAg) is a marker of wild-type hepatitis B virus replication. In resource-limited countries where access to enzyme-linked immunosorbent assay (ELISA) remains a challenge, rapid diagnostic tests (RDT) constitute a good alternative. The HBeAg status is employed to evaluate eligibility for antiviral therapy and to prevent the transmission of hepatitis B from mother to child (PMTCT). The objective of this study was to assess the diagnostic performance of the SD-Bioline®HBeAg RDT commonly used for detecting HBeAg in laboratories in Burkina Faso. The sample panel used was collected from HBsAg-positive patients received in the laboratory for the detection of HBeAg with the rapid test. The samples were retested for HBeAg using the VIDAS HBe/Anti-HBe enzyme-linked fluorescent assay (ELFA) (Gold standard). Then, the viral load (VL) of HBV DNA was determined using the GENERIC HBV CHARGE VIRLAE kit (GHBV-CV). The diagnostic performances of the SD-Bioline®HBeAg and its agreement with the gold standard were calculated with their 95% confidence intervals. Overall, 340 sera obtained from HBsAg-positive patients were included in this evaluation Compared to the VIDAS HBe/Anti-HBe ELFA test, the sensitivity (Se) and specificity (Sp) of the SD-Bioline®HBeAg test were 33.3% and 97.9%, respectively. The concordance between the two tests was 0.42. Depending on the viral load, the Se and Sp varied from 8.8% and 98.3% for a VL < 2000 IU/mL to 35.5% and 98.4% for a VL > 2,000,000 IU/mL. The results showed a low sensibility of the SD-Bioline®HBeAg RDT test, indicating that its use is inappropriate for the clinical management of HBV-infected patients. They also highlight the urgent need to develop HBeAg rapid tests with better sensitivities.

30 September 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
Armel M. SanouArmel M. Sanou
Armel M. Sanou
DNDelphine NAPON-ZONGO
Delphine NAPON-ZONGO
ACAbou Coulibaly
Abou Coulibaly
ITIna Marie Angèle Traore
Ina Marie Angèle Traore
AOAd Bafa Ibrahim Ouattara
Ad Bafa Ibrahim Ouattara
DKDramane Kania
Dramane Kania
Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI). Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral markers (HBsAg, anti-HCV) using rapid diagnostic tests. The proportions of HBsAg carriers and HCV exposure were calculated using Stata, and logistic regression was used to assess the impact of HBV vaccination on HBsAg carriage. Results: A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened for anti-HCV. Overall, the seroprevalence of HBsAg was 8.8% and 2.6% for anti-HCV. The results indicated that age, gender, and place of residence were associated with HBV infection. Conclusions: The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified.

7 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
MOMathuola Nina Genéviève Ouattara
Mathuola Nina Genéviève Ouattara
Armel M. SanouArmel M. Sanou
Armel M. Sanou
DNDelphine NAPON-ZONGO
Delphine NAPON-ZONGO
ACAbou Coulibaly
Abou Coulibaly
SKSylviane Korgo
Sylviane Korgo
HOHenri Gautier Ouedraogo
Henri Gautier Ouedraogo
GeneVac-B® was recently licensed in Burkina Faso and is widely used for population vaccination. This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-B® vaccine in Burkina Faso under actual conditions of use. This cross-sectional study included individuals fully vaccinated with GeneVac-B®. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire. Approximately 4 mL of whole blood was collected for immunological (anti-HBs, HBsAg, anti-HCV and anti-HIV) and biochemical (blood glucose, total cholesterol, and triglycerides) testing. The anti-HBs titer was used to determine the immune response. A total of 392 participants were included in the study. The mean age was 35.5±15 years. Approximately 56.1% had been previously exposed to HBV. Three hundred eighty (380) participants had an anti-HBs titer ≥ 12 mIU/mL, a seroprotection rate of 96.9%, and 12 had a titer < 12 mIU/mL, a nonresponse rate of 3.1%. Among the nonresponders, 11 (11/12; 91.7%) had high total cholesterol levels (> 240 mg/dL), and 8 (8/12; 66.7%) were older than 40 years of age. The results showed an excellent immune response to GeneVac-B® in our study population. However, age > 40 and high total cholesterol appear to be factors associated with nonresponse.

2 November 2024 in IJID Regions
Verified
Journal Article
Open access
NONina Genéviève Mathuola Ouattara
Nina Genéviève Mathuola Ouattara
Armel M. SanouArmel M. Sanou
Armel M. Sanou
DNDelphine NAPON-ZONGO
Delphine NAPON-ZONGO
ACAbou Coulibaly
Abou Coulibaly
SKSylviane Korogho
Sylviane Korogho
GOGautier Henri Ouédraogo
Gautier Henri Ouédraogo
Objective: This study aimed to evaluate the immune response in people fully vaccinated against hepatitis B with the GeneVac-BR circle vaccine in Burkina Faso under actual conditions of use. Methods: This cross-sectional study included individuals fully vaccinated with GeneVac-BR circle. For each consenting participant, sociodemographic and clinical data were collected using a structured questionnaire. Approximately 4 ml of whole blood was collected for immunological (anti-HBs, hepatitis B surface antigen, anti-hepatitis C virus, and anti-HIV) and biochemical (blood glucose, total cholesterol, and triglycerides) testing. The anti-HBs titer was used to determine the immune response. Results: A total of 392 participants were included in the study. The mean age was 35.5 +/- 15.3 years. Approximately 56% had been previously exposed to hepatitis B virus. Overall, 380 participants had an anti-HBs titer >= 12 mIU/ml indicating a seroprotection rate of 96.9%, and 12 had a titer < 12 mIU/ml, a nonresponse rate of 3.1%. Among the nonresponders, 11 (11/12; 91.7%) had high total cholesterol levels ( > 240 mg/dl), and 8 (8/12; 66.7%) were older than 40 years of age. Conclusions: The results showed an excellent immune response to GeneVac-BR circle in our study population. However, age > 40 and high total cholesterol appear to be factors associated with nonresponse.

2 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ADAbdoulaye DERA
Abdoulaye DERA
Armel M. SanouArmel M. Sanou
Armel M. Sanou
MOMathuola N. G. Ouattara
Mathuola N. G. Ouattara
AIAbdoul Kader Ilboudo
Abdoul Kader Ilboudo
DLDavid B. Lankoande
David B. Lankoande
MGMichel Kiréopori Gomgnimbou
Michel Kiréopori Gomgnimbou
Hepatitis B e antigen (HBeAg) is a marker of wild-type hepatitis B virus replication. In resource-limited countries where access to enzyme-linked immunosorbent assay (ELISA) remains a challenge, rapid diagnostic tests (RDT) constitute a good alternative. The HBeAg status is employed to evaluate eligibility for antiviral therapy and to prevent the transmission of hepatitis B from mother to child (PMTCT). The objective of this study was to assess the diagnostic performance of the SD-Bioline®HBeAg RDT commonly used for detecting HBeAg in laboratories in Burkina Faso. The sample panel used was collected from HBsAg positive patients received in the laboratory for the detection of HBeAg with the rapid test. The samples were retested for HBeAg using the VIDAS HBe/Anti-HBe enzyme-linked fluorescent assay (ELFA) (Gold standard). Then, the viral load (VL) of HBV DNA was determined using the GENERIC HBV CHARGE VIRLAE kit (GHBV-CV). The diagnostic performances of the SD-Bioline®HBeAg and its agreement with the gold standard were calculated with their 95% confidence intervals. 340 sera obtained from HBsAg positive patients were included in this evaluation Compared to the VIDAS HBe/Anti-HBe ELFA test, the sensitivity (Se) and specificity (Sp) of the SD-Bioline®HBeAg test were 33.3% and 97.9% respectively. The concordance between the two tests was 0.42. Depending on the viral load, the Se and Sp varied from 8.8% and 98.3% for a VL < 2,000 IU/mL to 35.5% and 98.4% for a VL > 2,000,000 IU/mL. The results showed a low Sensibility of the SD-Bioline®HBeAg RDT test, indicating that its use is inappropriate for the clinical management of HBV-infected patients. They also highlight the urgent need to develop HBeAg rapid tests with better sensitivities.